Af­ter No­var­tis left, Boehringer bets up to $500M on the field of pre­scrip­tion smart­phone apps

Boehringer In­gel­heim wants in on dig­i­tal ther­a­peu­tics.

The Ger­man phar­ma signed an up to $500 mil­lion col­lab­o­ra­tion with Click Ther­a­peu­tics, one of a hand­ful of ma­jor com­pa­nies de­vel­op­ing pre­scrip­tion com­put­er and smart­phone ap­pli­ca­tions for var­i­ous neu­ro­log­i­cal or men­tal dis­or­ders. They join a small list of phar­mas that have de­cid­ed to test the wa­ters in the emerg­ing field.

Un­der the deal, Boehringer and Click will co-de­vel­op a dig­i­tal ther­a­peu­tic for schiz­o­phre­nia, known as CT-155. It’s a com­ple­men­tary ef­fort to Boehringer’s more tra­di­tion­al schiz­o­phre­nia work. The com­pa­ny has con­cen­trat­ed their neu­ro­science ef­forts there since 2018, when a Phase II fail­ure blew up their late-stage Alzheimer’s ef­forts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA